Globant has expanded its AI-Native Services Platform, Glob.AI, by introducing Glob.AI OS, a unified operating system designed to govern and scale AI use across enterprises. This platform connects over 320 AI models, integrates corporate data and systems, and manages AI agents securely and efficiently. It enables companies to adopt AI at scale with governance, cost control, and auditability, supporting faster legacy modernization and product discovery. Glob.AI OS runs as SaaS or on clients' clouds, ensuring data privacy and offering measurable business outcomes through AI Pods supervised by experts.
Globant's expansion of its AI platform Glob.AI OS provides context for technology sector performance on Pluang as of Oct 28, 2026 02:21 WIB. Among 150 priced US technology stocks, 83 rose and 67 fell. Notably, NBIS gained 11.22% at USD 170.46 with a nearly balanced buy/sell order split, contrasting with CRDO's 10.39% rise at USD 166.86 despite predominantly sell orders (86%). Meanwhile, BBAI's price increased 10.38% to USD 2.34, with the longest typical hold time of 30 days among these movers.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
